ADding up biomarkers

While new Alzheimer's Association guidelines someday may affect early treatment decisions, drug developers already are identifying more immediate applications for use of brain imaging and cerebrospinal fluid testing to create and test new therapies.

The guidelines describe the use of imaging and cerebrospinal fluid (CSF) to detect AD before clinical signs of the disease appear. As reported by the general media, the guidelines pertain to the diagnosis of patients, which was buttressed last week by an opinion piece in Archives of Neurology...